
France Immunoassay Market Size, Share, Trends, Industry Analysis Report By Product (Reagents & Kits, Analyzers/Instruments), By Technology, By Specimen, By Application, By End Use – Market Forecast, 2025–2034
Description
The France Immunoassay Market size is expected to reach USD 1,602.94 million by 2034, according to a new study by Polaris Market Research. The report “France Immunoassay Market Share, Size, Trends, Industry Analysis Report By Product (Reagents & Kits, Analyzers/Instruments), By Technology, By Specimen, By Application, By End Use; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
An immunoassay refers to an antibody-based analytical method used to detect the presence or concentration of target molecules with high specificity and sensitivity. The France immunoassay market is driven by the shift toward automation and high-throughput screening platforms, which are transforming diagnostic workflows across clinical laboratories. Automated immunoassay systems are being increasingly adopted to reduce manual error, enhance consistency, and support large-volume testing, as demand increases for faster and more accurate results. This technological evolution is contributing to improved diagnostic precision and better patient outcomes, aligning with the country’s broader focus on healthcare efficiency.
The integration of immunoassays into personalized medicine approaches drives the France immunoassay market expansion opportunities. Immunoassays are proving instrumental in monitoring disease biomarkers and treatment responses with greater precision, as clinical decisions become more tailored to individual patient profiles. This personalized approach to diagnostics enables earlier intervention and more targeted therapies, reinforcing the strategic value of immunoassay technologies in clinical practice. The growing relevance of these tests in personalized healthcare frameworks highlights their expanding role in supporting France’s modern diagnostic ecosystem.
France Immunoassay Market Report Highlights
In terms of product, the reagents & kits segment accounted for USD 749.92 million revenue share in 2024, driven by widespread use in clinical diagnostics and research labs nationwide.
Based on technology, the rapid tests segment is projected to register a CAGR of 3.3%, fueled by France's shift toward decentralized diagnostics and preventive care for its aging population.
A few key France immunoassay market players include AAZ-LMB, Beckman Coulter, bioMérieux SA, DIAGAST, ELITechGroup SAS, Eurobio Scientific SA, Innovative Diagnostics, NG Biotech, Sebia SAS, and VedaLab.
Polaris Market Research has segmented the France immunoassay market report on the basis of product, technology, specimen, application, and end use:
By Product Outlook (Revenue, USD Million, 2020–2034)
Reagents & Kits
ELISA Reagents & Kits
Rapid Test Reagents & Kits
Western Blot Reagents & Kits
ELISPOT Reagents & Kits
Other Reagents & Kits
Analyzers/Instruments
Open Ended Systems
Closed Ended Systems
Software & Services
By Technology Outlook (Revenue, USD Million, 2020–2034)
Enzyme Immunoassays (EIA)
Chemiluminescence Immunoassays (CLIA)
Fluorescence Immunoassays (FIA)
Rapid Test
Radioimmunoassay (RIA)
Others
By Specimen Outlook (Revenue, USD Million, 2020–2034)
Blood
Urine
Saliva
Others
By Application Outlook (Revenue, USD Million, 2020–2034)
Infectious Disease Testing
Cardiology
Oncology
Endocrinology
Autoimmune Diseases
Therapeutic Drug Monitoring
Others
By End Use Outlook (Revenue, USD Million, 2020–2034)
Hospitals
Laboratories
Others
An immunoassay refers to an antibody-based analytical method used to detect the presence or concentration of target molecules with high specificity and sensitivity. The France immunoassay market is driven by the shift toward automation and high-throughput screening platforms, which are transforming diagnostic workflows across clinical laboratories. Automated immunoassay systems are being increasingly adopted to reduce manual error, enhance consistency, and support large-volume testing, as demand increases for faster and more accurate results. This technological evolution is contributing to improved diagnostic precision and better patient outcomes, aligning with the country’s broader focus on healthcare efficiency.
The integration of immunoassays into personalized medicine approaches drives the France immunoassay market expansion opportunities. Immunoassays are proving instrumental in monitoring disease biomarkers and treatment responses with greater precision, as clinical decisions become more tailored to individual patient profiles. This personalized approach to diagnostics enables earlier intervention and more targeted therapies, reinforcing the strategic value of immunoassay technologies in clinical practice. The growing relevance of these tests in personalized healthcare frameworks highlights their expanding role in supporting France’s modern diagnostic ecosystem.
France Immunoassay Market Report Highlights
In terms of product, the reagents & kits segment accounted for USD 749.92 million revenue share in 2024, driven by widespread use in clinical diagnostics and research labs nationwide.
Based on technology, the rapid tests segment is projected to register a CAGR of 3.3%, fueled by France's shift toward decentralized diagnostics and preventive care for its aging population.
A few key France immunoassay market players include AAZ-LMB, Beckman Coulter, bioMérieux SA, DIAGAST, ELITechGroup SAS, Eurobio Scientific SA, Innovative Diagnostics, NG Biotech, Sebia SAS, and VedaLab.
Polaris Market Research has segmented the France immunoassay market report on the basis of product, technology, specimen, application, and end use:
By Product Outlook (Revenue, USD Million, 2020–2034)
Reagents & Kits
ELISA Reagents & Kits
Rapid Test Reagents & Kits
Western Blot Reagents & Kits
ELISPOT Reagents & Kits
Other Reagents & Kits
Analyzers/Instruments
Open Ended Systems
Closed Ended Systems
Software & Services
By Technology Outlook (Revenue, USD Million, 2020–2034)
Enzyme Immunoassays (EIA)
Chemiluminescence Immunoassays (CLIA)
Fluorescence Immunoassays (FIA)
Rapid Test
Radioimmunoassay (RIA)
Others
By Specimen Outlook (Revenue, USD Million, 2020–2034)
Blood
Urine
Saliva
Others
By Application Outlook (Revenue, USD Million, 2020–2034)
Infectious Disease Testing
Cardiology
Oncology
Endocrinology
Autoimmune Diseases
Therapeutic Drug Monitoring
Others
By End Use Outlook (Revenue, USD Million, 2020–2034)
Hospitals
Laboratories
Others
Table of Contents
129 Pages
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Retail and E-Commerce
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. France Immunoassay Market Insights
- 4.1. France Immunoassay Market – Material Snapshot
- 4.2. France Immunoassay Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Government Initiatives and Healthcare Modernization
- 4.2.1.2. Rising Infectious Disease Burden
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Regulatory Challenges and Market Fragmentation
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. France Immunoassay Market Material Trends
- 4.6. Value Chain Analysis
- 5. France Immunoassay Market, by Product
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. France Immunoassay Market, by Product, 2020-2034 (USD Million)
- 5.3. Reagents & Kits
- 5.3.1. France Immunoassay Market, by Reagents & Kits, 2020–2034 (USD Million)
- 5.3.2. ELISA Reagents & Kits
- 5.3.2.1. France Immunoassay Market, by ELISA Reagents & Kits, 2020–2034 (USD Million)
- 5.3.3. Rapid Test Reagents & Kits
- 5.3.3.1. France Immunoassay Market, by Rapid Test Reagents & Kits, 2020–2034 (USD Million)
- 5.3.4. Western Blot Reagents & Kits
- 5.3.5. France Immunoassay Market, by Western Blot Reagents & Kits, 2020–2034 (USD Million)
- 5.3.6. ELISPOT Reagents & Kits
- 5.3.6.1. France Immunoassay Market, by ELISPOT Reagents & Kits, 2020–2034 (USD Million)
- 5.3.7. Other Reagents & Kits
- 5.3.7.1. France Immunoassay Market, by Other Reagents & Kits, 2020–2034 (USD Million)
- 5.4. Analyzers/Instruments
- 5.4.1. France Immunoassay Market, by Analyzers/ Instruments, 2020–2034 (USD Million)
- 5.4.2. Open Ended Systems
- 5.4.2.1. France Immunoassay Market, by Open Ended Systems, 2020–2034 (USD Million)
- 5.4.3. Closed Ended Systems
- 5.4.3.1. France Immunoassay Market, by Closed Ended Systems, 2020–2034 (USD Million)
- 5.5. Software & Services
- 5.5.1. France Immunoassay Market, by Software & Services, 2020–2034 (USD Million)
- 6. France Immunoassay Market, Technology
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. France Immunoassay Market, Technology, 2020-2034 (USD Million)
- 6.3. Enzyme Immunoassays (EIA)
- 6.3.1. France Immunoassay Market, by Enzyme Immunoassays (EIA), 2020–2034 (USD Million)
- 6.3.2. Chemiluminescence Immunoassays (CLIA)
- 6.3.2.1. France Immunoassay Market, by Chemiluminescence Immunoassays (CLIA), 2020–2034 (USD Million)
- 6.3.3. Fluorescence Immunoassays (FIA)
- 6.3.3.1. France Immunoassay Market, by Fluorescence Immunoassays (FIA), 2020–2034 (USD Million)
- 6.4. Rapid Test
- 6.4.1. France Immunoassay Market, by Rapid Test, 2020–2034 (USD Million)
- 6.5. Radioimmunoassay (RIA)
- 6.5.1. France Immunoassay Market, by Radioimmunoassay (RIA), 2020–2034 (USD Million)
- 6.6. Others
- 6.6.1. France Immunoassay Market, by Others, 2020–2034 (USD Million)
- 7. France Immunoassay Market, by Specimen
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. France Immunoassay Market, by Specimen, 2020-2034 (USD Million)
- 7.3. Blood
- 7.3.1. France Immunoassay Market, by Blood, 2020–2034 (USD Million)
- 7.4. Urine
- 7.4.1. France Immunoassay Market, by Urine, 2020–2034 (USD Million)
- 7.5. Saliva
- 7.5.1. France Immunoassay Market, by Saliva, 2020–2034 (USD Million)
- 7.6. Others
- 7.6.1. France Immunoassay Market, by Others, 2020–2034 (USD Million)
- 8. France Immunoassay Market, by Application
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. France Immunoassay Market, by Application, 2020-2034 (USD Million)
- 8.3. Infectious Disease Testing
- 8.3.1. France Immunoassay Market, by Infectious Disease Testing, 2020–2034 (USD Million)
- 8.4. Cardiology
- 8.4.1. France Immunoassay Market, by Cardiology, 2020–2034 (USD Million)
- 8.5. Oncology
- 8.5.1. France Immunoassay Market, by Oncology, 2020–2034 (USD Million)
- 8.6. Endocrinology
- 8.6.1. France Immunoassay Market, by Endocrinology, 2020–2034 (USD Million)
- 8.7. Autoimmune Diseases
- 8.7.1. France Immunoassay Market, by Autoimmune Diseases, 2020–2034 (USD Million)
- 8.8. Therapeutic Drug Monitoring
- 8.8.1. France Immunoassay Market, by Therapeutic Drug Monitoring, 2020–2034 (USD Million)
- 8.9. Others
- 8.9.1. France Immunoassay Market, by Others, 2020–2034 (USD Million)
- 9. France Immunoassay Market, by End Use
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. France Immunoassay Market, by End Use, 2020-2034 (USD Million)
- 9.3. Hospitals
- 9.3.1. France Immunoassay Market, by Hospitals, 2020-2034 (USD Million)
- 9.4. Laboratories
- 9.4.1. France Immunoassay Market, by Laboratories, 2020-2034 (USD Million)
- 9.5. Others
- 9.5.1. France Immunoassay Market, by Others, 2020-2034 (USD Million)
- 10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
- 11. Company Profiles
- 11.1. AAZ-LMB
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Beckman Coulter
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. bioMérieux SA
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. DIAGAST
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. ELITechGroup SAS
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Eurobio Scientific SA
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Innovative Diagnostics
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. NG Biotech
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Sebia SAS
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. VedaLab
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.